1009 ECP A2
BioCentury & Getty Images

Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

A2 will use its $71.5M series B to advance up to three clinical solid tumor programs

A2 uses its dual engineered T cell platform to kill tumor cells while protecting healthy cells by targeting the loss of genetic material.

Oct 9, 2020 | 10:14 PM GMT


Read the full 630 word article

How to gain access

Continue reading with a
two-week free trial.